ADGRG6 and pancreatic adenocarcinoma: The analyses strikingly suggested that ADGRG6 had potential as both a prognostic marker and a therapeutic target for PAAD, which was further supported by data from multiple PAAD cohorts from the Gene Expression Omnibus (GEO) database.